IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?

Expert Review of Clinical Immunology

Volumn 12, Issue 8, 2016, Pages 849-855

  Giacomelli, Roberto ^a   Ruscitti, Piero ^a   Alvaro, Saverio ^a   Ciccia, Francesco ^b   Liakouli, Vasiliki ^a   Di Benedetto, Paola ^a   Guggino, Giuliana ^b   Berardicurti, Onorina ^a   Carubbi, Francesco ^a   Triolo, Giovanni ^b   Cipriani, Paola ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

biologic drug; IL 1 blocking agents; IL 1 ; macrophage; pathogenesis; Rheumatoid arthritis; type 2 diabetes

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; BLOCKING ANTIBODY;

CYTOKINE PRODUCTION; DRUG EFFICACY; HUMAN; MACROPHAGE; MONOCYTE; MONONUCLEAR CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS; ANIMAL; ARTHRITIS, RHEUMATOID; COMORBIDITY; DIABETES MELLITUS, TYPE 2; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PROCEDURES;

ANIMALS; ANTIBODIES, BLOCKING; ARTHRITIS, RHEUMATOID; COMORBIDITY; DIABETES MELLITUS, TYPE 2; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-1BETA;

EID: 84963623585     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2016.1168293     Document Type: Review

References (80)

1. M.Y.Donath, S.E.Shoelson Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11:98–107.•• This study provides an excellent overview of inflammatory mechanisms associated to T2D.
2. C.A.Dinarello, M.Y.Donath, T.Mandrup-Poulsen. Role of IL-1beta in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes. 2010;17:314–321.
3. G.Cavalli, C.A.Dinarello. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford). 2015;54:2134–2144.• An Interesting review of efficacy of interleukin-1 blocking therapies in the treatment of rheumatological diseases and co-morbidities.
4. K.P.Liao, D.H.Solomon. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford). 2013;52:45–52.
5. C.Murdoch, M.Muthana, C.E.Lewis. Hypoxia regulates macrophage functions in inflammation. J Immunol. 2005;175:6257–6263.
6. B.Burke, A.Giannoudis, K.P.Corke, et al. Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol. 2003;163:1233–1243.
7. K.Eguchi, I.Manabe. Macrophages and islet inflammation in type 2 diabetes. Diabetes Obes Metab. 2013;15:152–158.• An interesting review of role of macrophages in T2D.
8. C.A.Dinarello, T.Ikejima, S.J.Warner, et al. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1in rabbits in vivo and in human mononuclear cells in vitro. J Immunol. 1987;139:1902–1910.
9. F.Martinon, A.Mayor, J.Tschopp. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229–265.
10. C.Garlanda, C.A.Dinarello, A.Mantovani. The interleukin-1 family: back to the future. Immunity. 2013;39:1003–1018.
11. C.A.Dinarello. Overview of the interleukin-1 family of ligands and receptors. Semin Immunol. 2013;25:389–393.
12. P.Ruscitti, P.Cipriani, F.Carubbi, et al. The role of IL-1β in the bone loss during rheumatic diseases. Mediators Inflamm. 2015;2015:782382.
13. V.Strand, A.F.Kavanaugh. The role of interleukin-1 in bone resorption in rheumatoid arthritis. Rheumatology (Oxford). 2004;43:iii10–iii16.
14. W.P.Arend. Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. Semin Arthritis Rheum. 2001;30:1–6.
15. W.B.van den Berg, B.Bresnihan. Pathogenesis of joint damage in rheumatoid arthritis: evidence of a dominant role for interleukin-I. Baillieres Best Pract Res Clin Rheumatol. 1999;13:577–597.
16. L.L.Johnson, R.Dyer, D.J.Hupe. Matrix metalloproteinases. Curr Opin Chem Biol. 1998;2:466–471.
17. S.B.Abramson, A.Amin. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology. 2002;41:972–980.
18. E.M.Gravallese. Bone destruction in arthritis. Ann Rheum Dis. 2002;61:ii84–86.
19. S.C.Ghivizzani, R.Kang, H.I.Georgescu, et al. Constitutive intra-articular expression of human IL-1 beta following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis. J Immunol. 1997;1:3604–3612.
20. R.Horai, S.Saijo, H.Tanioka, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med. 2000;191:313–320.
21. E.M.Gravallese, C.Manning, A.Tsay, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000;43:250–258.
22. H.Takayanagi, H.Iizuka, T.Juji, et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2000;43:259–269.
23. L.A.Joosten, M.M.Helsen, F.A.van de Loo, et al. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra. Arthritis Rheum. 2008;58:S110–S122.
24. L.A.Joosten, M.M.Helsen, T.Saxne, et al. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol. 1999;163:5049–5055.
25. S.S.Makarov, J.C.Olsen, W.N.Johnston, et al. Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc Natl Acad Sci U S A. 1996;93:402–406.
26. K.Otani, I.Nita, W.Macaulay, et al. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J Immunol. 1996;156:3558–3562.
27. U.Müller-Ladner, C.R.Roberts, B.N.Franklin, et al. Human IL-1Ra gene transfer into human synovial fibroblasts is chondroprotective. J Immunol. 1997;158:3492–3498.
28. J.Li, H.C.Hsu, J.D.Mountz. Managing macrophages in rheumatoid arthritis by reform or removal. Curr Rheumatol Rep. 2012;14:445–454.
29. A.Mantovani, A.Sica, S.Sozzani, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677–686.
30. D.M.Mosser, J.P.Edwards. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958–969.
31. S.Tsai, P.Santamaria. MHC class II polymorphisms, autoreactive T-cells, and autoimmunity. Front Immunol. 2013;4:321.
32. G.Chen. Immunotherapy of rheumatoid arthritis targeting inflammatory cytokines and autoreactive T cells. Arch Immunol Ther Exp (Warsz). 2010;58:27–36.
33. M.Mertens, J.A.Singh. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev. 2009;1:CD005121.• A systematic review of anakinra efficacy in RA patients.
34. H.J.Lachmann, I.Kone-Paut, J.B.Kuemmerle-Deschner, et al. Canakinumab in CAPS study group: use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416–2425.
35. R.Alten, H.Gram, L.A.Joosten, et al. The human anti-IL-1beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10:R67.
36. R.Alten, J.Gomez-Reino, P.Durez, et al. Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study. BMC Musculoskelet Disord. 2011;12:153.
37. K.Maedler, P.Sergeev, F.Ris, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest. 2002;110:851–860.•• This study provides the first description of the role of IL-1β in T2D.
38. N.Welsh, M.Cnop, I.Kharroubi, et al. Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets? Diabetes. 2005;54::3238–3244.
39. R.Zhou, A.Tardivel, B.Thorens. et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 2010 Feb;11(2):136–140. doi:10.1038/ni.1831. Epub 2009 Dec20.
40. S.L.Masters, A.Dunne, S.L.Subramanian, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol. 2010;11:897–904.
41. R.Akter, P.Cao, H.Noor, et al. Islet amyloid polypeptide: structure, function, and pathophysiology. J Diabetes Res. 2016;2016:2798269.
42. B.Prajapati, P.K.Jena, P.Rajput, et al. Understanding and modulating the toll like receptors (TLRs) and NOD like receptors (NLRs) cross talk in type 2 diabetes. Curr Diabetes Rev. 2014;10:190–200.
43. K.Schroder, R.Zhou, J.Tschopp. The NLRP3 inflammasome: a sensor for metabolic danger? Science. 2010;327:296–300.
44. M.Böni-Schnetzler, J.Thorne, G.Parnaud, et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab. 2008;93:4065–4074.
45. M.Boni-Schnetzler, S.Boller, S.Debray, et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology. 2009;150:5218–5229.
46. K.Maedler, P.Sergeev, J.A.Ehses, et al. Leptin modulates β cell expression of IL-1 receptor antagonist and release of IL-1β in human islets. Proc Natl Acad Sci USA. 2004;101:8138–8143.
47. M.Y.Donath, D.J.Gross, E.Cerasi, et al. Hyperglycemia-induced β-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes. 1999;48:738–744.
48. W.Quan, E.K.Jo, M.S.Lee. Role of pancreatic β-cell death and inflammation in diabetes. Diabetes Obes Metab. 2013;15:141–151.
49. S.Akira, T.Misawa, T.Satoh, et al. Macrophages control innate inflammation. Diabetes Obes Metab. 2013;15:10–18.
50. L.Banaei-Bouchareb, M.Peuchmaur, P.Czernichow, et al. A transient microenvironment loaded mainly with macrophages in the early developing human pancreas. J Endocrinol. 2006;188:467–480.
51. K.G.Riley, R.C.Pasek, M.F.Maulis, et al. Macrophages are essential for CTGF-mediated adult β-cell proliferation after injury. Mol Metab. 2015;4:584–591.
52. D.A.Hume, D.Halpin, S.Charlton, et al. The mononuclear phagocyte system of the mouse defined by immunohistochemical localization of antigen F4/80. Macrophages of endocrine organs. Proc Natl Acad Sci USA. 1984;81:4174–4177.
53. K.Eguchi, I.Manabe, Y.Oishi-Tanaka, et al. Saturated fatty acid and TLR signaling link β cell dysfunction and islet inflammation. Cell Metab. 2012;15:518–533.
54. M.R.Dasu, S.Devaraj, I.Jialal. High glucose induces IL-1beta expression in human monocytes: mechanistic insights. Am J Physiol Endocrinol Metab. 2007;293:E337–E346.
55. H.M.Lee, J.J.Kim, H.J.Kim, et al. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes. 2013 Jan;62(1):194–204.
56. M.El Muayed, L.K.Billings, M.R.Raja, et al. Acute cytokine-mediated downregulation of the zinc transporter ZnT8 alters pancreatic beta-cell function. J Endocrinol. 2010;206:159–169.
57. K.Maedler, D.M.Schumann, N.Sauter, et al. Low concentration of interleukin-1beta induces FLICE-inhibitory protein-mediated beta-cell proliferation in human pancreatic islets. Diabetes. 2006;55:2713–2722.
58. D.M.Schumann, K.Maedler, I.Franklin, et al. The Fas pathway is involved in pancreatic beta cell secretory function. Proc Natl Acad Sci USA. 2007;104:2861–2866.
59. W.Suarez-Pinzon, O.Sorensen, R.C.Bleackley, et al. Beta-cell destruction in NOD mice correlates with Fas (CD95) expression on beta-cells and proinflammatory cytokine expression in islets. Diabetes. 1999;48:21–28.
60. D.L.Eizirik, S.Sandler, N.Welsh, et al. Interleukin-1 beta-induced stimulation of insulin release in mouse pancreatic islets is related to diacylglycerol production and protein kinase C activation. Mol Cell Endocrinol. 1995;111:159–165.
61. H.Ellingsgaard, I.Hauselmann, B.Schuler, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med. 2011;17:1481–1489.
62. A.M.Skeldon, M.Faraj, M.Saleh. Caspases and inflammasomes in metabolic inflammation. Immunol Cell Biol. 2014;92:304–313.• An interesting review of role of caspases and inflammasomes in metabolic inflammation.
63. M.Y.Donath. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov. 2014;13:465–476.• An interesting review of immunomodulatory therapies for T2D.
64. A.Moran, B.Bundy, D.J.Becker, et al. AIDA Study Group: interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet. 2013;381:1905–1915.
65. I.Koné-Paut, C.Galeotti. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome. Expert Rev Clin Immunol. 2015;11:1083–1092.
66. I.Koné-Paut, C.Galeotti. Anakinra for cryopyrin-associated periodic syndrome. Expert Rev Clin Immunol. 2014;10:7–18.
67. C.M.Larsen, M.Faulenbach, A.Vaag, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356:1517–1526.•• A clinical study showed the efficacy of treatment with an IL-1 antagonist in T2D patients.
68. C.M.Larsen, M.Faulenbach, A.Vaag, et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care. 2009;32:1663–1668.
69. J.A.Ehses, G.Lacraz, M.H.Giroix, et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci USA. 2009;106:13998–14003.
70. N.S.Sauter, F.T.Schulthess, R.Galasso, et al. The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology. 2008;149:2208–2218.
71. E.J.P.van Asseldonk, R.Stienstra, T.B.Koenen, et al. Treatment with anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2011;96:2119–2126.
72. P.C.van Poppel, E.J.van Asseldonk, et al. The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance. Diabetes Obes Metab. 2014;16:1269–1273.
73. M.K.Roell, H.Issafras, R.J.Bauer, et al. Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity. J Biol Chem. 2010;285:20607–20614.
74. C.Cavelti-Weder, A.Babians-Brunner, C.Keller, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care. 2012;35:1654–1662.
75. A.Rissanen, C.P.Howard, J.Botha, et al. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes Metab. 2012;14:1088–1096.
76. P.M.Ridker, C.P.Howard, V.Walter, et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012;126:2739–2748.
77. M.Osiri, Y.Sattayasomboon. Prevalence and out-patient medical costs of comorbid conditions in patients with rheumatoid arthritis. Joint Bone Spine. 2013;80:608–612.
78. P.Ruscitti, P.Cipriani, P.Di Benedetto, et al. Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3 (NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. Clin Exp Immunol. 2015;182:35–44.
79. P.Ruscitti, P.Cipriani, L.Cantarini, et al. Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. J Med Case Rep. 2015;9:123.
80. B.Missler-Karger, M.Leu, M.A.Raboisson, et al. FRI0219 Disease severity, no steroid use and type ii diabetes predict response to anakinra (kineret(R)) in patients with rheumatoid arthritis. Ann Rheum Dis. 2013;72:447.